IRLAB Therapeutics AB (publ) (FRA:6IRA)

Market Cap	25.79M +32.5%
Revenue (ttm)	7.16M +4.7%
Net Income	-4.86M
EPS	-0.06
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,040
Open	0.1738
Previous Close	0.1820
Day's Range	0.1738 - 0.1738
52-Week Range	0.1048 - 0.1868
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 13, 2026

About IRLAB Therapeutics AB

IRLAB Therapeutics AB (publ) discovers and develops drugs for the treatment of Parkinson’s disease and other central nervous system (CNS) disorders in the United States. The company develops Mesdopetam (IRL790), which has completed both a Phase IIb clinical trial for the treatment of levodopa-induced dyskinesias, and a Phase I clinical trial for the treatment of Parkinson’s disease psychosis; Pirepemat (IRL752), which is in a Phase IIB clinical trial to reduce the risk of falling and falls in Parkinson’s disease, and in a Phase IIA clinical tri...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Employees: 31
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 6IRA

Financial Performance

In 2025, IRLAB Therapeutics AB's revenue was 57.46 million, a decrease of -39.28% compared to the previous year's 94.63 million. Losses were -110.01 million, 32.3% more than in 2024.

Financial numbers in SEK

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Oct 26, 2026

Data Sources Report a data error